Condition: Postmenopausal Women Osteoporosis · Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.
This study is a multicenter, randomized, double-blinded, parallel-group Phase III clinical study to compare the clinical efficacy, safety, and immunogenicity of 9MW0311 and Prolia® in Chinese postmenopausal women with osteoporosis at high risk for fracture.
This description comes directly from the study's public registry record.
Zhitian Hu · 86-10-87708016 · zhitian.hu@Mabwell.com
Always discuss trial participation with your own doctor first.
| Mabwell (Shanghai) Bioscience Co., Ltd. | Beijing, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06804590